Is seputinib/serpatinib a domestic or imported targeted drug?

Selpercatinib, also called Selpercatinib, is an oral small molecule inhibitor for the targeted treatment of RET gene fusion or mutation-related cancers. It is an imported original drug. The drug is produced by Loxo, a subsidiary of the American pharmaceutical company Eli Lilly (Eli Lilly) Oncology was developed and was first approved by the U.S.FDA in 2020 for the treatment of RETConfluent non-small cell lung cancer (NSCLC), RETmutant thyroid cancer and RETfusion medullary thyroid cancer, etc. SelpercatinibThe research and development is an important breakthrough in the field of precision medicine, specifically targeting tumors driven by specific genes, providing more targeted treatment options for RET positive patients.

As an imported original drug, Selpercatinib was not initially launched in China. Patients need to purchase it through overseas medical channels, such as original drugs in the United States, Europe, Japan and other places. In recent years, with the acceleration of my country's drug review and approval system, Selpercatinib has been approved for marketing in China, becoming the first RET-targeted drug in China. Despite this, the drug is still an imported drug developed by a foreign company, and its production and quality standards are still controlled by the original foreign manufacturer. It has undergone a large number of international verifications in terms of efficacy, safety, and clinical application.

In terms of efficacy, Selpercatinibhas shown a high objective response rate (ORR) in patients with RET fusion-positive non-small cell lung cancer, and the effect is also more significant in patients with brain metastases. In addition, the drug also demonstrated good disease control rate and tolerability in patients with RET mutated medullary thyroid cancer. Compared with traditional chemotherapy or non-specific targeted drugs, Selpercatinib has fewer side effects and is convenient to take, which greatly improves patients' quality of life.

In general, Selpercatinib (Selpercatinib) is an imported targeted drug with clear targets and precise efficacy, especially suitable for discovery through genetic testingRETFor patients with genetically altered lung or thyroid cancer. Since the drug is still under foreign patent protection, the price is relatively high, and it has not yet been fully included in domestic medical insurance. Patients should weigh their economic conditions and doctor's advice when choosing.

Reference materials:https://en.wikipedia.org/wiki/Selpercatinib